Announced Tue, 30 Jun · 22:00 IST
Glenmark: U.S. FDA issues 6 procedural observations at Goa plant
Regulatory & Legal View source PDF
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.7%1-day move
₹2202.40
prior close
₹2196.40
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.3-0.4-0.7-1.5-0.7+0.4+3.2+2.5+1.2+3.5+0.2———
Up moveDown movePending
AI summary
The U.S. FDA completed a GMP inspection at Glenmark's Goa manufacturing facility from June 22 to June 30, 2026, issuing a Form 483 with six observations. None relate to data integrity, and all are procedural and non-repeat. The company expects no impact on supply of commercial products and will respond to the FDA within the required timeline.
Likely market impact
Form 483 is a routine observation notice. Procedural, non-repeat and non-data-integrity findings are usually manageable, sentiment likely neutral.